@article{oai:kanazawa-u.repo.nii.ac.jp:00014340,
 author = {Fushida, Sachio and Kaji, Masahide and Oyama, Katsunobu and Hirono, Yasuo and Nezuka, Hideaki and Takeda, Toshiya and Tsukada, Tomoya and Fujimoto, Daisuke and Ohyama, Shigekazu and Fujimura, Takashi and Ohta, Tetsuo},
 journal = {OncoTargets and Therapy},
 month = {Feb},
 note = {The standard regimen of second-line chemotherapy for patients with unresectable gastric cancer has not been established. However, weekly paclitaxel (wPTX) has become the preferable second-line chemotherapy in Japan. Histone deacetylase (HDAC) inhibitors have been shown to have antiproliferative activity through cell-cycle arrest, differentiation, and apoptosis in gastric cancer cells. One HDAC inhibitor, valproic acid (VPA), also inhibits tumor growth by inducing apoptosis, and enhances the efficacy of paclitaxel in a mouse xenograft model of gastric cancer. wPTX plus VPA as a second-line chemotherapy is expected to improve survival in gastric cancer patients. A multicenter randomized Phase II study was conducted to compare the effects of wPTX plus VPA and wPTX alone. A total of 66 patients participated in this study. The primary end point of the study was overall survival, and secondary end points were progression-free survival, response rate, and assessment of peripheral neuropathy. © 2015 Fushida et al.},
 pages = {939--941},
 title = {Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer},
 volume = {8},
 year = {2015}
}